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AbstrAct
This Explanation and Elaboration (E&E) article expands 
on the 26 items in the Standards for UNiversal reporting 
of Decision Aid Evaluations guidelines. The E&E provides 
a rationale for each item and includes examples for 
how each item has been reported in published papers 
evaluating patient decision aids. The E&E focuses 
on items key to reporting studies evaluating patient 
decision aids and is intended to be illustrative rather 
than restrictive. Authors and reviewers may wish to use 
the E&E broadly to inform structuring of patient decision 
aid evaluation reports, or use it as a reference to obtain 
details about how to report individual checklist items.
bAckground
This Explanation and Elaboration 
(E&E) document provides authors with 
additional guidance and examples of 
how to report the 26 items included in 
the Standards for UNiversal reporting 
of Decision Aid Evaluations (SUNDAE) 
reporting guideline (see online 
appendix A).1 For each item, the E&E 
provides a brief rationale for the impor-
tance of that item, cross-referencing 
to other items as appropriate and 
including evidence for inclusion where 
available. It also provides selected 
examples, explains how those examples 
illustrate good reporting and notes any 
additional content that might further 
improve the quality of reporting.
Development of the E&E built upon the 
methods used to develop the SUNDAE 
checklist.1 Evidence and definitions were 
drawn from the literature, including the 
2014 update of the International Patient 
Decision Aid Standards (IPDAS) Collabo-
ration guidelines and the 2014 and 2017 
Cochrane reviews of patient decision aids 
(PDAs).2–4 Online appendix B provides a 
table summarising the types of rationale 
and evidence supporting the inclusion of 
each item in the checklist.
The aim of the SUNDAE E&E is to 
support authors in demonstrating the 
rigour of their research through high-
quality reporting. Previous reviews of 
PDA reports revealed notable gaps in 
reporting that limit the replicability of 
the studies, the reviews of the evidence 
supporting PDAs, the identification of 
appropriate PDAs for use clinically and 
the potential classification of tools that 
meet the minimum standards for certifica-
tion.3 5–7 Improved reporting may support 
systematic reviews and, in turn, inform 
best practices and policies regarding certi-
fication and implementation of PDAs.
using the sundAe explAnAtion 
And elAborAtion document
Some readers may wish to read the 
whole document, but others may find 
it more useful as a reference document 
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for individual items. Although the checklist items are 
organised by standard manuscript sections (eg, Intro-
duction, Methods), we recognise that for some items 
there may be flexibility as to where in the paper they 
are included. For example, the listing of the options 
included within the PDA may be fully met within the 
Introduction or could be included in the Methods 
section.
We recognise that authors may not be able to 
include all items in one evaluation paper, particularly 
given some editorial restrictions. Some items may be 
addressed within an appendix or other supplemental 
material that have become increasingly available with 
online publications. Items related to development of 
the PDA may already be available in published papers 
or other reports of the development of the PDA (eg, 
needs assessments, usability/acceptability testing, pilot 
studies); in such cases, a reference to the development 
paper will meet reporting requirements. However, if 
space allows, we encourage brief reporting of items 
published elsewhere in the evaluation report, as 
these are often the only reports included in system-
atic reviews. Similarly, fidelity and process evaluation 
items may be included in the evaluation paper, or be 
published separately. Some items may be reported 
together within an individual article. For example, 
fidelity assessment may be seen as part of process eval-
uation (items 14 and 15) and reported together.
The examples were selected from published PDA 
evaluation reports to represent a variety of study 
designs, clinical/public health contexts and interna-
tional writing styles. In some cases, multiple exam-
ples are included as individual examples may not be 
comprehensive. Longer examples were edited for 
length to exclude extraneous material, but excerpts 
were not edited to ensure consistent use of termi-
nology or to improve the quality of reporting. We 
did not impose any other specific criteria in selecting 
examples for inclusion. These reporting guidelines are 
not meant to inappropriately constrain authors. There 
is a risk that strict adherence to guidelines of any sort 
may be counterproductive.8 While we recommend 
that authors pay careful attention to the guidelines, we 
also encourage authors to prepare their manuscripts as 
clearly and concisely as possible.
explAnAtion And elAborAtion of sundAe 
guidelines items
title/Abstract
As part of a standard title and abstract:
Item 1
Use the term patient decision aid in the abstract to 
identify the intervention evaluated and, if possible, in 
the title.
A wide range of terms have been used in the litera-
ture on PDAs, often interchangeably. There is currently 
no distinct MESH heading for literature searching; 
however, the most widely used term is patient decision 
aid, as incorporated within the Cochrane review and 
the title of IPDAS.2 3 Other terms used include deci-
sion aid, patients’ decision aid and decision support 
intervention/technology. The term patient decision 
aid refers to evidence-based tools designed to help 
patients to participate in making specific and deliber-
ated choices among healthcare options.4 The Delphi 
process strongly supported using the term patient 
decision aid for these reporting guidelines to support 
consistency and to ease identification of relevant 
studies when searching the literature.
Example 1
Evaluation of the effect of a patient decision aid about 
vasectomy on the decision-making process: a rand-
omized trial.9
Example 2
Randomised controlled trial  of a patient decision aid 
for colorectal cancer screening.10
Explanation
The chosen examples state in the title that a PDA has 
been evaluated.
Item 2
In the abstract, identify the main outcomes used to 
evaluate the patient decision aid.
Identifying the main outcomes can be a challenge 
in reporting PDA evaluations. Including the main 
outcomes in the abstract immediately helps the reader 
identify the key measures of impact. It also indicates 
the focus of the study (eg, on decision-making process, 
decision quality or some other measure, such as clin-
ical outcomes or resource use). Further detail of the 
measures and instruments used should be included in 
the Methods section (see items 17 and 18). Including 
standard, descriptive terms for key outcomes in the 
abstract (eg, Decision Conflict Scale) will greatly assist 
with searching and indexing.11 12
Example 1
The primary outcome was informed choice (defined 
as adequate knowledge and consistency between atti-
tudes and screening intentions)….13
Example 2
The primary outcome was patients' intention to 
undergo screening for prostate cancer, assessed imme-
diately after reading the decision aid. In addition to 
giving their answer, patients were systematically asked 
to cite the reasons for those answers by responding to 
open-ended questions.14
Example 3
The aim of this study was to evaluate, in a factorial rand-
omized controlled trial, whether simple (information 
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video/leaflet) and complex (decision analysis) decision 
aids for treatment of hypertension were associated 
with changes in decisional conflict, anxiety, treatment 
intentions, and actual treatment choice in a sample of 
newly diagnosed hypertensive patients.15
Explanation
These examples clearly state the main outcomes. 
The first example incorporates an outcome measure 
of decision quality, as recommended by the IPDAS 
Collaboration.11 The second includes a measure of 
the patient’s intention, as well as seeking to capture 
reasons for the stated intention. The third example 
lists a range of measures.
introduction
As part of standard introduction:
Item 3
Describe the decision that is the focus of the patient 
decision aid.
A critical component of a paper reporting an evalu-
ation of a PDA is a description of the decision or deci-
sions being supported by the PDA, to enable the reader 
to understand the clinical context and the intended 
audience for the intervention (see item 4). This was 
strongly confirmed in the Delphi process. The deci-
sion should be mentioned briefly in the Introduction, 
and/or Title, but expanded on in the Methods section, 
where the PDA is described in more detail (see items 
10, 11 and 12).
Example 1
This paper describes … the Yorkshire Dialysis Deci-
sion Aid (YoDDA) booklet,16 and investigates (a) its 
acceptability to people making dialysis decisions, and 
(b) the feasibility of evaluating its effectiveness within 
usual care.17 [Introduction]
The YoDDA booklet is designed for people with 
worsening kidney disease, and their family members, 
to make informed decisions between 2 dialysis options 
delivered in 2 ways, in the context of their lifestyle: 
hemodialysis, in a medical centre or at home; perito-
neal dialysis, at home in an automated or continuous 
ambulatory form.17 [Methods]
Example 2
The purpose of the present study was to determine 
whether the addition of the Decision Board to the 
medical consultation improved patient knowledge and 
satisfaction with decision making compared with the 
medical consultation alone for women with lymph 
node-negative breast cancer considering adjuvant 
chemotherapy.18 [Introduction]
[The Decision Board] contains detailed information 
tailored to the individual on a patient’s treatment choices 
(chemotherapy or no chemotherapy).18 [Methods]
Explanation
The examples demonstrate the decision being 
supported. Example 1 briefly refers to the decision in 
the Introduction (the YoDDA booklet). The reader can 
see this is a PDA about dialysis, but specification of the 
treatment options occurs in the Methods section (see 
item 10). Example 2 describes the decision as being 
about adjuvant chemotherapy in lymph node-negative 
breast cancer, and clarifies the options (chemotherapy/
no chemotherapy) in the Methods section.
Item 4
Describe the intended user(s) of the patient decision 
aid. 
A description of the intended user(s) of the PDA 
helps readers assess the generalisability of findings to 
practice, and understand who is expected to appro-
priately use the decision aid. This description should 
be available in the Abstract/Introduction, potentially 
with further detail in the Methods section (see items 
13 and 19).
Example 1
For this study, we selected patients to be eligible for 
prostatectomy as well as radiotherapy. In most previous 
studies comparing prostate cancer treatments, patients’ 
characteristics differed. For example, surgery patients 
were often younger and had less advanced tumours 
then irradiated patients. By selecting, this study aimed 
to involve a more homogeneous population that actu-
ally had a choice. The aim of this study was to examine 
the effect of a decision aid on the treatment choice 
for localized prostate cancer in men who really have 
a choice.19
Example 2
Our objective was to evaluate the impact of a PDA on 
decisional conflict of middle-aged women who were 
considering NHPs [natural health products] for meno-
pausal symptoms… Inclusion criteria were: (1) women 
aged from 45 to 64 years; (2) suffering from symptoms 
of menopause; (3) considering NHPs for their meno-
pausal symptoms…20
Explanation
These examples describe the rationale for selecting 
participants for the evaluation study and linking it 
explicitly to the intended users of the PDA. Further 
details are given of the patients studied (especially in 
example 2). The study participants are patients at the 
same point in their care pathway as intended patient 
users in clinical practice.
Item 5
Summarise the need for the patient decision aid under 
evaluation.
It is important that PDA evaluation reports explain 
the need for the specific PDA so that readers and 
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reviewers may assess the appropriateness and potential 
value of the intervention. Justification might include, 
for example, evidence that patients do not know or 
understand the options available or are making poor 
quality decisions, geographical variation in uptake of 
options suggesting underuse or overuse, mismatch 
between patient values and the options chosen or lack 
of support to make and implement decisions.
Example 1
Current guidelines no longer indicate a single treat-
ment as the optimal treatment of localized prostate 
carcinoma. Therefore, patients should be involved in 
the treatment decision, which calls for the use of deci-
sion aids.19
Example 2
Benign prostatic hyperplasia (BPH) is a common 
condition affecting roughly 25% of older men. These 
men face a choice of "watchful waiting" or active treat-
ment, either medical or surgical. Although prosta-
tectomy rates have declined recently, this procedure 
remains the second most common major operation 
among Medicare-age men, with 311,000 performed 
in the United States in 1991. Moreover, considerable 
geographical variation has been reported for prosta-
tectomy. A recent BPH practice guideline, noting these 
variations, has recommended a shared decision-making 
approach to treatment.21
Explanation
The above examples clearly state the need for each 
specific PDA. Both examples make it explicit that an 
intervention is needed to support decision making 
given that there is more than one reasonable option 
for treatment. Example 2 gives a broader rationale 
including the choice of options, evidence of geograph-
ical variation and recommendation from a published 
clinical guideline.
Item 6
Describe the purpose of the evaluation study with 
respect to the patient decision aid.
Consistent with other reporting guidelines, a 
clear statement of the purpose (aims/objectives) of 
the evaluation study helps readers and reviewers 
judge the appropriateness of the study design, 
outcomes used and data analysis as well as to criti-
cally appraise the findings of the study. This item is 
important specifically to PDAs because of the need 
to link the evaluation to the explicit and intended 
purpose of the PDA. For many evaluation reports, 
the aim of the study will be consistent with the 
purpose of the PDA; however, some reports may 
include evaluation within a broader study (eg, 
multicomponent interventions). This item should 
be found in the Introduction, but may well be 
expanded in the Methods section, particularly if 
the evaluation of the PDA is a subaim of the overall 
study (see items 13 and 15).
Example 1
The objective of this study was to estimate the effect of 
the Depression Choice decision aid on the quality of 
the decision-making process and depression outcomes 
… We hypothesized that its use during the clinical 
encounter would improve patient engagement, the 
quality of decision making as perceived by patients and 
clinicians, and depression outcomes.22
Example 2
This paper describes the development and field-testing 
process used to create the virtual decision lab, which 
had three primary objectives … The second objec-
tive was to test the [Options for Managing Your Knee 
Osteoarthritis Pain] web-based decision aid in terms 
of its performance compared with the video-booklet 
decision aid used in clinical practice.23
Explanation
The above examples clearly state the purpose of the 
evaluation of the PDA. Example 1 also highlights 
several helpful details about the evaluation: assessed 
with both decision process and outcome measures, 
as used during the clinical encounter, and by both 
patients and clinicians. These items would then be 
explained further in the Methods section (see items 
13 and 15). Example 2 illustrates how evaluation of a 
specific PDA may be nested within a larger study (eg, 
multicomponent evaluation, dissemination and imple-
mentation study).
methods
Studies with a comparator should also address items 
7–13 for the comparator, if possible.
Item 7
Briefly describe the development process for the patient 
decision aid (and any comparator), or cite other docu-
ments that describe the development process. At a 
minimum, include the following:
 ► Participation of stakeholders in its development
 ► The process for gathering, selecting and appraising evi-
dence to inform its content
 ► Any testing that was done
The importance of systematic, rigorous and repli-
cable development of PDAs has been summarised 
within the IPDAS programme.24 Furthermore, in the 
most recent Cochrane review of PDAs, only about 
half of PDAs reported having involved patients in 
their development process in some way.4 Expert 
consensus suggests that key features of the devel-
opment process include participation of stake-
holders in the development process, a high-quality 
process for gathering, selecting and appraising 
evidence to inform its content, and pilot testing of 
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the intervention.25 A full description of the develop-
ment process may be published separately (eg, in a 
protocol or development paper), but all evaluation 
reports should include a brief statement and/or refer-
ence to the development methods. This may include 
noting the theoretical framework, the process for 
gathering, selecting and appraising evidence, the 
inclusion of all stakeholders in development and 
reference to any formative studies (eg, pilot studies, 
acceptability studies). Development methods for 
comparators should also be described or referenced 
where possible; if ‘usual care’ is the comparator, this 
should be described.
Example 1
Details on the design, development and preliminary 
evaluation of the decision board for the surgical treat-
ment of breast cancer are described elsewhere.26 The 
decision board was based on a systematic review of 
randomized trials comparing mastectomy to breast 
conserving therapy and qualitative interviews and 
focus groups with women with breast cancer and their 
surgeons regarding informational needs for decision 
making.27
Example 2
To ensure that our design process addressed multiple 
users’ needs, we formed a stakeholder advisory panel 
consisting of four patients, two clinicians, two deci-
sion scientists, two decision counselors, and two 
health informaticians. The advisory panel selected 
three publications to guide development. … Six iter-
ative cycles of review and revision refined the paper 
and online prototypes. Groups of five patients walked 
through paper drafts of each component and were 
asked to comment on the wording, format, and visual 
layout. The drafts were revised in accordance with 
their comments, and iteratively presented to a new 
set of five patients, then revised again. Once feedback 
reached saturation, the advisory panel rereviewed 
the optimized paper drafts and approved them 
for programming … Four focus groups of patients 
(n = 4 each) iteratively reviewed the prototypes 
online. Finally, the advisory panel re-appraised the 
patient decision aid using the IPDAS Collaboration’s 
criteria, and approved the research platform for initial 
field-testing in the clinic.23
Explanation
Example 1 illustrates how a reference to a published 
paper on development, plus a brief summary state-
ment, can provide enough information for readers to 
identify that a structured PDA development has taken 
place and to access the detail from the original paper, 
if needed. Example 2 provides more detail about the 
role of stakeholders, use of a framework and prelimi-
nary testing studies in preparing the PDA for the eval-
uation study.
Item 8
Identify the patient decision aid evaluated in the study 
(and any comparator) by including:
 ► Name or information that enables it to be identified
 ► Date and/or version number
 ► How it can be accessed, if available.
Readers of reports of PDA evaluation studies should 
be able to uniquely identify and access the PDA, any 
accompanying interventions and/or comparators for 
several reasons. They may be interested to view them 
as part of interpreting the specific evaluation study; 
they may wish to implement them in practice; they may 
be involved in data extraction for systematic review or 
meta-analysis; and/or they may wish to confirm they 
meet the minimum characteristics of a PDA.28–30
Of 17 RCTs in a recent review of the quality of PDA 
reporting, only 2 included complete PDAs within the 
article, 2 referenced URLs providing complete PDAs 
and 3 referenced URLs where part of the PDA was 
provided.5 Seven articles required the authors to access 
the PDA to confirm the characteristics of the interven-
tion.5 Being able to access and view PDAs can result in 
better assessments of study quality and provide more 
complete data for future meta-analyses.
This item could be completed in a number of ways, 
ideally by including the name and version number 
in the article and how the PDA can be accessed. To 
provide access, the PDA might be included as an 
appendix or online resource, by reference to another 
published paper that includes the PDA or by reference 
to another source (eg, website or database of PDAs). 
The referenced PDA should be the version of the 
PDA that was evaluated within the published study; 
although reference to an updated version may also 
be appropriate, it should be clear which version was 
evaluated. Such information may be found in different 
sections of the paper, primarily in the Introduction or 
Methods (see also items 12 and 13).
Example 1
The [colorectal cancer] screening decision aid, called 
CHOICE [Communicating Health Options through 
Interactive Computer Education, version 6.0W], was 
based on a previously validated videotape decision 
aid.17-18 The program is designed to be accessible to 
low-literacy patients by using easy-to-understand audio 
segments, video clips, graphics, and animations.31
Example 2
In preparation for our trial, we developed a decision 
aid [informed choice about breast cancer screening] 
(the intervention; appendix pp 3–14), then produced a 
control version for comparison (appendix pp 15–18).13
Example 3
Using the FRAX calculator,7–8 … our group devel-
oped an encounter decision aid in 2008, the Osteopo-
rosis Choice decision aid, to facilitate shared decision 
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making during the clinical encounter9 … we sought to 
determine the effect of the Osteoporosis Choice deci-
sion aid compared with usual care with and without 
the FRAX fracture risk calculator.
To facilitate the exploration of this tool in prac-
tice, our group has made freely available an electronic 
version of the tool for stand-alone use or integrated 
into the electronic medical record. The tool can be 
found here:  http:// osteoporosisdecisiona id. mayo clin 
ic. org.32
Explanation
The above examples demonstrate three approaches 
to reporting this item. Example 1 includes in-text 
mention of the PDA name, version number and refer-
ences to earlier versions, and provides a screenshot of 
the PDA in the article. Example 2 is one in which the 
PDA and control are published as an appendix with 
the paper. Example 3 names the PDA and comparator, 
provides references for both and provides a URL for 
direct access to the PDA.
Item 9
Describe the format(s) of the patient decision aid (and 
any comparator) (e.g., paper, online, video).
PDAs come in a range of formats and media (eg, 
print, audio, video, digital), and various accompanying 
channels or modes of delivery (eg, in consultation, in 
the community, on the web) that may affect the reach, 
accessibility and interactivity of the PDA, as well as its 
usability, implementation and sustained use. See also 
item 13 on mode of delivery and we note that authors 
sometimes confuse format and mode of delivery. A 
few randomised studies suggest that the format of 
PDAs and accompanying interventions can affect deci-
sion-making outcomes.33 34 There also appears to be 
consensus that several factors intrinsic to format affect 
reach, accessibility, interactivity, tailoring of informa-
tion and outcomes.12 35–40
Example 1
The study used a 2×2 factorial comparison of discus-
sion and video formats for presenting men informa-
tion about PSA testing…
1. Usual care (n=43):  … 
2. Discussion (n=45): Participants listened to a lecture 
which closely followed the content of the videotape The 
PSA Decision: What You Need to Know (PSA video), de-
veloped by the Foundation for Informed Medical Deci-
sion Making. The lecture took between 25 and 30 min. 
Following the lecture, participants were invited to ask 
questions and discuss the lecture content.
3. Video (n=46): Participants viewed the 25 min PSA video. 
The videotape was previously evaluated and described by 
Flood et al.9
4. Video and discussion (n=42): Participants viewed the 
25 min PSA video. Following the videotape, participants 
were given an opportunity to ask questions and discuss 
the content of the videotape with a moderator. Group 
discussions following the video averaged 7 minutes in 
length.33
Example 2
Our intervention included a combined lifestyle and 
medication adherence intervention delivered in two 
alternate formats: counsellor-delivered or web-based. 
Participants in both arms received a computerized 
decision aid and then either 7 sessions of counseling 
from a counselor or 7 sessions of interactive tailored 
messaging on the web (up to 5.5 hours of interventional 
contact; see Fig. 2 [in original paper]). In designing the 
intervention, our goal was to deliver the same content 
in both formats. Thus, we designed the scripted coun-
seling and written materials in the counselor arm to 
match the text of the web-based intervention and used 
the same sequencing of materials for both interven-
tions.41
Explanation
The above examples state the alternate formats for 
delivery. Example 2 uses the same format of PDA in 
each arm, but alternate formats (eg, print and web) 
and modes (predominantly in person in the clinic or 
at home on the web) of the accompanying counsel-
ling intervention to support decision follow-through. 
These examples also directly address interactivity and 
tailoring, and other factors that might moderate the 
PDA effect (eg, content, time spent).
Item 10
List the options presented in the patient decision aid 
(and any comparator).
The 2013 IPDAS Collaboration guidelines update 
stated that, ‘it is important that PDAs present all the rele-
vant options and the information about those options 
in a complete, unbiased and neutral manner that is 
sustained throughout the PDA’s content and format’.42 
Explicitly listing the options ensures that readers can 
assess whether the intervention meets one of the quali-
fying criteria of a PDA (ie, presenting a decision about 
two or more medically relevant options, and whether 
all medically relevant and patient-relevant options are 
included, such as starting/changing/stopping active 
therapies, and/or no treatment, ‘watchful waiting’ or 
active surveillance).29 Additional detail (see items 11 
and 12) may be provided in a figure (eg, screenshot of 
a web-based tool), appendix, reference to a develop-
mental paper and/or URL. The authors should consider 
reporting any rationale for why potentially relevant 
options (including ‘no treatment’) were excluded from 
the PDA. For systematic review and meta-analysis, 
listing the options presented in each PDA also allows 
reviewers to assess the appropriateness of cross-com-
parisons of PDAs, studies and papers. It also allows a 
potential implementer to determine the applicability to 
their patient group or health system provision.
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Example 1
The web-based decision aid … educated patients about 
CHD [coronary heart disease], their predicted global 
CHD risk, their risk factors, and the benefits and harms 
of the most effective risk reducing strategies (aspirin, 
cholesterol medication, hypertension medication, and 
smoking cessation)…43
Example 2
The decision aid was a decision support booklet struc-
tured in two parts. The first part provided information 
about the use of the decision aid, what the prostate 
is, what prostate cancer is, the stages and grades of 
cancer, treatment options (surgery, radiation therapy, 
and watchful waiting), …44
Explanation
Both examples explicitly list the treatment or risk 
reduction options included in the PDA.
Item 11
Indicate the components in the patient decision aid 
(and any comparator) including:
 ► Explicit description of the decision*
 ► Description of health problem*
 ► Information on options and their benefits, harms and 
consequences*
 ► Values clarification (implicit or explicit)*
 ► Numerical probabilities
 ► Tailoring of information or probabilities
 ► Guidance in deliberation
 ► Guidance in communication
 ► Personal stories
 ► Reading level or other strategies to help understanding
 ► Other components.
*These components are needed to meet the defini-
tion of a patient decision aid.
Items 11 and 12 focus on the components of the 
PDA. Item 11 indicates the need to list the components. 
Item 12 indicates the need to describe the compo-
nents. The rationale for listing the components is so 
that readers can assess whether it meets the criteria for 
categorisation as a PDA (starred components) and can 
readily see which components are included. A recent 
analysis of RCTs of PDAs showed that the majority 
meet the criteria for qualifying as a PDA.5 29 Explicit 
listing of the components also supports systematic 
reviews and meta-analyses, for example, exploring the 
contributions of different component parts of PDAs to 
effectiveness.
Example 1
The decision aid comprises an interactive computer 
program provided on a CD-ROM. It presents up-to-
date, evidence-based information about abdominal 
aortic aneurysms and their treatment options, elective 
aneurysm surgery and watchful waiting, and the pros 
and cons of those treatment options, as is required 
by European law … For patients with aneurysms of 
at least 5.5 cm, the decision aid provided a compre-
hensive insight into the balance of benefit and harm 
of a surgical (open and endovascular) and a conserva-
tive approach, taking age, comorbidity, and size of the 
aneurysm into account. The program also includes a 
number of questions that invite the patient to clarify 
his or her preferences. For example, “To what extent 
would you be anxious or worried about rupture if you 
do not get surgical treatment?”45
Example 2
The decision aid [for patients with recently diagnosed 
prostate cancer] was a decision support booklet struc-
tured in two parts. The first part provided information 
about use of the decision aid, what the prostate is, what 
prostate cancer is, stages and grades of cancer, treat-
ment options (surgery, radiation therapy, and watchful 
waiting); the chance of intermediate outcomes (bene-
fits and risks of each treatment option); the chance of 
long-term outcomes for the three different options 
and potential adverse effects (eg, urinary inconti-
nence, erectile dysfunction, and the specific effects of 
radiotherapy) associated with treatment choice. All of 
this information was summarized into tables, with the 
different risks and benefits of each treatment clearly 
outlined to ensure that patients could visually compare 
the differences.
In the second part, the decision aid included a section 
with examples of questions to ask health professionals, 
three short descriptions of the experiences of three 
patients who had chosen different treatments, clari-
fication of the patients’ own values for each benefit 
and risk, and assistance in the final decision-making 
process. This last personal section included four steps 
to assist the patient in the decision-making process: 
(1) clarification of ideas, (2) identification of needs to 
make the decision, (3) exploration of needs, and (4) 
approach to steps to be taken.44
Explanation
Both examples succinctly state which components are 
included in the PDA and it can be seen that they meet 
the core criteria for a PDA. Additional detail (see item 
12) may be provided in text, supplementary appen-
dices or by web link to the PDA.
Item 12
Briefly describe the components from item 11 that are 
included in the patient decision aid (and any compar-
ator) or cite other documents that describe the compo-
nents.
Expanding on item 11, descriptions of the compo-
nents of the PDA (and comparator, where rele-
vant) allow for more in-depth consideration of 
the completeness and quality of the PDA and its 
component parts. Ideally, the description should be 
in sufficient detail such that readers of the report 
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know exactly what was included, and systematic 
reviews comparing studies have adequate informa-
tion to compare components and features. If suffi-
cient detail cannot be provided within the evaluative 
report, additional information should be provided 
through referencing development paper(s) or 
providing access to the PDA (eg, figures, supplemen-
tary appendix, URL—see item 8). Items 11 and 12 
that list and describe the interventions are usually 
reported in the Methods section.
Example 1
Based on the Ottawa Decision Support Framework, 
the advisory panel structured the patent decision aid 
in four deliberative steps.46
Step 1: Information comprehension … The deci-
sion aid presented up-to-date clinical information 
about the natural history of knee osteoarthritis, 
non-surgical options, surgical options and poten-
tial risks/benefits … The decision aid presented the 
clinical information at an overview level in plain 
language, with available audio voiceover. Patients 
who desired additional detail could choose inter-
active ‘More Information’ links. It then provided a 
side-by-side summary of the treatment options and 
attributes. Step 1 ended with two optional Personal 
Decision Activities, where patients could: (a) self-
quiz their knowledge of the key facts and (b) docu-
ment questions for their doctor.
Step 2: Values clarification … The narrator discussed 
the importance of considering whether some attributes 
of particular procedures are more important than 
others. Narrative examples illustrated this … Finally, 
step 2 presented two interactive Personal Decision 
Activities in which the patient could: (a) rate the 
importance of each option’s attributes on a 0-star to 
5-star scale and (b) indicate an initially-favored option 
that best matched the attributes they valued most.
Step 3: Considering social resources … The narrator 
described strategies for managing positive and nega-
tive pressures to choose a particular option, and for 
communicating one’s preferences with others … Step 
3 presented two interactive Personal Decision Activi-
ties in which the patient could: (a) list who else might 
be involved in the decision process and identify what 
the patient would like their role to be and (b) docu-
ment specific questions they had for these individuals.
Step 4: Forming an action plan … The narrator 
discussed strategies for creating (a) short-term action 
items to address any gaps in information, clarity or 
personal support and (b) a long-term plan. Step 4 
ended with an optional Personal Decision Activity, 
where patients could interactively create their personal 
short-and/or long-term action plans.
In closing, the website summarized participants’ 
responses into their printable Personal Decision 
Summary and provided links to references and related 
resources.23
Example 2
The therapeutic options presented on the DB [deci-
sion board for invasive treatment of primary or 
secondary carious lesions in pre-molars and molars] 
are no therapy, gold cast, amalgam, ceramic, simplified 
composite (bulk-filled QuiXfil; Dentsply, Konstanz, 
Germany) in combination with a self-adhesive bonding 
(XenoV; Dentsply) and composite restoration with 
incremental filling technique (Ceram●X mono; Dent-
sply) in combination with an etch-and-rinse adhesive 
(Optibond Fl; Kerr).
The factors shown on the DB are ‘survival rate’, 
‘treatment time’, ‘costs’/‘self-payment’ and ‘charac-
teristics’. The described criteria, except for time and 
cost, were based on reviews about survival rates(12,15) 
and comparison of material properties.(16) The ‘char-
acteristics’ are substance loss, side effects and abrasion/
mastication comfort.
The criterion ‘survival rate’ was presented in natural 
frequencies with positive and negative notation. 
According to the literature, this form of presentation 
is the most non-judgemental and comprehensible one 
from the patients’ point of view.(17) The treatment costs 
were calculated according to the national guidelines 
for medical fees for the statutory system and private 
health insurance funds (BEMA and GOZ).47
Explanation
Example 1 describes several components in detail 
including information on options and their attrib-
utes, guidance on communication (eg, support to list 
specific questions), values clarification exercises and 
action planning support. Example 2 includes evidence-
based information on the options, on their risks and 
benefits, including numerical probabilities based on 
natural frequencies, and on the costs incurred.
Item 13
Describe the delivery of the patient decision aid (and 
any comparator) including details such as:
 ► How it was delivered (eg, by whom and/or by what 
method)
 ► To whom it was delivered
 ► Where it was used
 ► When it was used in the pathway of care
 ► Any training to support delivery
 ► Setting characteristics and system factors influencing its 
delivery.
PDAs are complex interventions and their delivery is 
as important as the components described in items 11 
and 12. Several aspects of PDA delivery—for example, 
where, when, how, to whom and by whom it was deliv-
ered, and the characteristics of the setting in which it 
was delivered—can influence whether and how it is 
used by intended users, which in turn, may influence 
its efficacy and replicability. Details on all aspects of 
PDA delivery are required to enable other researchers 
to replicate or build on research findings and interpret 
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whether the PDA was delivered and used as intended 
(see items 14 and 21), explain outcomes of the eval-
uation and assess generalisability to other health-ser-
vice contexts. In addition, these details are required to 
enable decisions about policy, health service manage-
ment, commissioning, design and cost.
Limited research has compared the effect of different 
delivery approaches on use and efficacy of the PDAs. 
An RCT by Jones et al (2009) found improvements 
in knowledge and a trend towards better acceptability 
and less decisional conflict when the PDA was deliv-
ered by clinicians during the visit than when it was 
delivered by clinician-researchers before the visit.48 
Frosch et al.'s trial comparing delivery of PDA through 
internet or video found that participants receiving 
the PDA through video were more likely to review 
the materials than those receiving the PDA through 
the internet.49 See also item 9 (format and mode of 
delivery are interlinked but authors sometimes confuse 
them or use these terms interchangeably).
Example 1
Between November 2006 and June 2007, the decision 
aid [prostate cancer screening] was delivered in inter-
vention sites through tablet computers made avail-
able in common gathering areas (e.g., break rooms, 
cafeterias). We elected to make computers available 
in public spaces, with the assumption that visibility 
would generate interest and, thus, promote participa-
tion. Each location afforded sufficient privacy so that 
DA users could sit individually and view the computer 
screen without their responses being seen by others. 
Headphones were provided. The DA was designed to 
be independently administered even for those with 
minimal or no computer skills. A health educator 
was available to provide assistance with computers if 
needed, although no individual required assistance, 
other than initial start-up of the program. We used 
multiple strategies to publicize and promote the inter-
vention, including posters placed in high visibility 
areas, distribution of fliers, announcements made at 
regularly scheduled meetings and provision of small 
incentives (e.g., key ring flashlights). Computers were 
made available in work sites at prespecified days, based 
on agreements between management and study staff. 
The computers were available during the day, gener-
ally in 6-hour periods, based on managements' request. 
Each site had at least three computers available on site 
for a minimum of 15 days over the 3-month inter-
vention period (roughly once per week). Men were 
allowed release-time from work to use the DA. Infor-
mation was saved at each time of use; men could 
either complete the DA session at one time or return at 
multiple time points to complete it (mean time spent, 
28 min). At the conclusion of the session, men were 
provided with a printed tailored report summarizing 
their estimated risk for [cancer of the prostate], assess-
ment of pros/cons, decisional status and pages visited 
during DA use. This report was designed to facilitate 
communication about screening with primary care 
providers.50
Example 2
The intervention was a multifaceted program based 
on shared decision-making concepts. The program 
included physician training, a decision board for use 
during the consultation that was handed out to the 
patients after the medical encounter, and printed 
patient information that combined evidence-based 
knowledge about depression care with specific 
encouragement for patients to be active in the deci-
sion-making process. Physicians in the intervention 
group completed modules on guideline-concordant 
depression care. The modules also included content 
on enhancing skills for involving patients in the deci-
sion-making process during the medical encounter.
The theoretical framework for the shared deci-
sion-making portion of the modules was based on 
the work of Towle and Godolphin32 and Elwyn 
and colleagues.33–35 Specific aspects of the modules 
included specialized lectures with accompanying 
questions and discussion rounds, facilitation practice, 
role-playing and video exemplars of high-quality 
shared decision making. Standardized case vignettes 
and case studies from the general practice were used. 
The training took place within a 6-month time period, 
which included five scheduled training program 
events, each including four discrete modules. Atten-
dance was consistently high: 17 physicians (85%) 
attended the first event, 15 (75%) the following two 
events, 16 (80%) attended the fourth event and 19 
(95%) attended the last event. Eleven physicians 
(55%) attended all five events and nine (45%) at 
least three training sessions. Additional details about 
the conceptual basis of the training program, the 
program events, specific modules and evaluation of 
the training program is published elsewhere.36 All 
intervention physicians were given decision aids and 
patient information leaflets for dissemination to the 
patients.
The decision aid was used during the deci-
sion-making consultation. It contained details about 
the symptoms of the disease to certify the diagnoses, 
information about the treatment options, their pros 
and cons and a support for the patients’ value clarifica-
tion. The patient information leaflet was based on the 
Clinical Practice Guideline on Depression in Primary 
Care of the Agency for Healthcare and Policy Research 
[www. ahrq. gov] and contained information about the 
diagnosis and therapy of the disease, addresses health 
beliefs, coping strategies, involvement of relatives and 
presents tips to foster the involvement of patients in 
the treatment decision making, e.g., patients’ prepara-
tion for the medical encounter.51
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Example 3
Participants were mailed the relevant booklet [PDA 
for colorectal cancer screening] for their age and 
gender and a questionnaire which they were asked to 
complete and return. A faecal occult blood test kit was 
not included with the package, but information was 
provided about how to obtain one.52
Explanation
All three examples describe the delivery of the PDA 
by giving details on the delivery aspects applicable in 
their specific context. All give details on how the PDA 
was delivered—example 1, through readily accessible 
tablet computers to be used independently; example 2, 
a decision board; example 3 posted out to the partici-
pants. Example 1 describes ‘to whom’ the decision aid 
was delivered: to male staff.
They clearly describe ‘where’ the PDA was intended 
to be used; in example 1 on computers within the 
workplace; in example 2 in the clinic and in example 
3 implicitly in the home setting. They describe when 
the PDA was used in the clinical pathway of care—
in examples 1 and 3, the PDA on screening is deliv-
ered to individuals who have not yet entered a care 
pathway as they are considering whether or not to 
have screening. In example 2, the extract gives little 
detail about the patients’ place in the pathway, but it 
can be established from the information elsewhere in 
the paper that the PDA was to be used with patients 
newly diagnosed with depressive disorders during the 
consultation where a decision about treatment was to 
be made.
The examples describe whether or not health profes-
sionals/researchers were involved in the delivery, 
and, where so, describe any training they received to 
support delivery. In example 1, health professionals/
researchers were not directly involved in delivery—
the PDA was designed to be used independently, with 
assistance on computers available from health educa-
tors; example 2 is very clear about the physicians 
involved in delivering the PDA and extensively states 
the training delivered to them prior to using the PDA. 
In example 3, the patient is expected to review the 
PDA at home without explicit health professional or 
researcher input.
Finally, they describe aspects of the setting or system 
factors that may influence the PDA delivery beyond 
the immediate clinical or research setting in which it is 
delivered. Example 1 describes in detail various system 
and setting factors that characterised the context of 
PDA delivery, which may in turn influence the PDA 
update and use. For instance, they describe using a 
range of strategies to promote the PDA and to make 
it widely and easily accessible (eg, incentives, posters, 
fliers, announcements), having a high level of buy-in 
from the management in the form of release time for 
employees, availability of quiet space and computers. 
In example 2, it is apparent that the training component 
is a significant element in supporting the delivery of 
the PDA.
Item 14
Describe any methods used to assess the degree to 
which the patient decision aid was delivered and used 
as intended (also known as fidelity).
Fidelity is a key methodological requirement of any 
intervention study in order to show whether or not the 
intervention was delivered and used as planned and 
in the same way for all participants (sometimes called 
delivery and implementation fidelity). Implementa-
tion fidelity is a component of process evaluation and 
helps the reader assess why the intervention works 
or does not work (see item 15). This might include a 
description of the methods used to determine whether 
or not the PDA was viewed/read/used as planned and 
in some situations the length of exposure to the PDA 
(eg, number of minutes of the video observed; length 
of time using it or which components of an online 
PDA were accessed and for how long). Reporting 
how fidelity was assessed may enhance understanding 
of factors influencing success/failure of the PDA (see 
items 15, 21 and 24). This item may be reported 
together with item 15.
Example 1
The website monitored whether participants 
reviewed the assigned intervention [ prostate cancer 
screening PDA] before their appointments. Men who 
had not clicked on the assigned link within a week 
before their appointment received an email reminding 
them to review the intervention… .  Rates of review of 
the educational materials in the four groups were also 
compared by logistic regression.53
Example 2
We also assessed, by reviewing the video-recorded 
encounters, the fidelity with which the decision aid 
was delivered and used as intended during these 
encounters using the osteoporosis fidelity checklist.54 
This scale is comprises 10 items (present/absent scale), 
and results are presented as the percentage of items 
present.32
Example 3
In addition to a condition-specific educational 
pamphlet [prostate cancer PDA], participants 
received a maximum of two tailored telephone 
education calls within 1 month … by trained gradu-
ate-level health educators. Treatment fidelity checks 
were conducted on 44% of calls. Trained raters 
listened to audiotaped calls and checked whether key 
points were covered and the interventionist spoke at 
an appropriate pace, addressed questions and probed 
appropriately.55
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Explanation
Example 1 describes limited monitoring of whether 
patients viewed the PDA, without specifying detail of 
viewing component parts, but allowing analysis to be 
undertaken to reveal differential access across compar-
ison groups to support interpretation of results (see 
item 21). It also incorporates a mechanism to increase 
use. Example 2 describes use of a fidelity checklist 
applied to video recordings of the consultation to 
assess fidelity of use of an in-consultation PDA, as well 
as testing for contamination across into the control arm 
by capturing clinician behaviour. Example 3 describes 
the method for assuring fidelity of the tailored educa-
tion telephone calls alongside the pamphlet PDA.
Item 15
Describe any methods used to understand how and 
why the patient decision aid works (also known as 
process evaluation) or cite other documents that 
describe the methods.
Process evaluation is increasingly recognised 
and recommended as a key component of evalua-
tions of complex interventions, when the impact of 
the interventions may be highly dependent on the 
context within which they are delivered. It has been 
defined as ‘a study which aims to understand the 
functioning of an intervention, by examining imple-
mentation, mechanisms of impact, and contextual 
factors. Process evaluation is complementary to, but 
not a substitute for, high quality outcomes evalua-
tion’.56 It is an assessment undertaken to understand 
how and why a PDA works or does not work in a 
specific study, and links back to fidelity in item 14. 
Process evaluations explore implementation issues 
and contextual factors within the trial. They help to 
distinguish between ineffective interventions (failure 
of intervention) and badly delivered interventions 
(implementation failure). They can illuminate the 
reasons behind effectiveness or ineffectiveness, thus 
potentially contribute to understanding the active 
ingredients of an intervention and the way that an 
intervention is actually delivered in practice. They 
may also help describe barriers and facilitators to 
implementation that may be of value to those who 
wish to implement the intervention in a different 
context. In some circumstances, they may allow for 
adaptation of the trial at an early stage to maximise 
the efficiency or quality of the evaluation.57 Process 
evaluations may be published within the report of the 
evaluation or sometimes as a separate report.
Example 1
The process evaluation of this study consisted of:
1. Open interviews with a sample of 15 patients who 
did and did not receive the allocated intervention … . 
A verbatim transcript was created for each interview. 
Coding and analysis was performed with the  ATLAS. ti 
software package.
2. Researcher observation of clinicians discussing imple-
mentation of the intervention during clinical meetings, 
which were recorded in a notebook by a research assis-
tant. Themes of interest were identified by the research 
team and further discussed with the clinical teams when 
necessary.
3. A questionnaire-based survey among clinicians 
consisting of three parts: (1) investigating their attitude 
towards shared decision making and the use of a 
web-based decision aid … ; (2) examining potential 
hampering factors for shared decision making … ; 
and (3) exploring to what extent clinicians considered 
patients to be capable and interested in shared decision 
making … 
This process evaluation provided data to shed light 
on how well the intervention was implemented, to 
what extent the trial outcomes were related to the 
quality of the implementation and the setting in which 
it was implemented and what processes might have 
mediated these relations.58
Example 2
A parallel qualitative study, Thematic Observational 
Analysis of DARTSII [Decision Analysis in Routine 
Treatment Study II], was conducted alongside the 
RCT of the DARTSII decision support tool. Multiple 
methods were used to understand the interactional 
processes of the trial consultations and participants’ 
experiences and understandings of the trial and of 
any advice they were given. The first 30 participants 
recruited to the RCT were invited to take part in the 
qualitative study  … , With participants’ consent, 
consultations (n=29) across the three arms of the trial 
were video recorded.
Within 5 days of the consultation, participants 
(n=30) were interviewed about general issues related 
to their experience of [atrial fibrillation], their expe-
rience of the consultation and their understanding 
of how, and what, treatment decisions were reached 
within it. Participants (n=26) were interviewed for a 
second time 90–100 days after the consultation. This 
interview elicited participants’ views of the specific 
consequences they attributed to the consultation, their 
post hoc evaluation of the decision reached and the 
extent to which they believed that their expectations 
had been met.59
Explanation
Example 1 was included within the report of the 
RCT and describes several complementary methods 
used. It includes a clear description of the methods 
applied, and a rationale for the process evaluation 
(what it was intended to add to the trial). Example 
2 was published alongside, and cited within, the 
report of the linked RCT. Both describe mixed 
methods approaches with quantitative and qualita-
tive elements (see item 23).
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Item 16
Identify theories, models or frameworks used to guide 
the design of the evaluation and selection of study 
measures.
To enable researchers, PDA developers and service 
providers to interpret and build on the findings from 
PDA evaluation studies, it is important the authors 
describe the frameworks, models and/or theories used 
to evaluate their PDA, making explicit the links between 
the PDA and methods and measures used in the eval-
uation. These frameworks, models and/or theories 
guide the questions asked, measures used and inter-
pretation of analysis and discussion.60 Theories enable 
us to understand, predict and change phenomena or 
processes by providing a framework within which 
to develop and test hypotheses, and interpret data.61 
The rationale for which measures are used is key to 
understanding if the PDA worked to support people’s 
decision making, and engagement with health profes-
sionals, and also whether or not using a PDA impacts 
on healthcare and patient-reported outcomes. There 
is underuse and under-reporting of the theories used 
in developing and evaluating PDAs.3 6 Without a theo-
retical framework or rationale to guide the choice of 
measures, evidence about how and why PDAs work, 
and in what contexts, will continue to be limited. These 
findings are essential to understanding the mechanisms 
of why PDAs work in practice, and how they can be 
integrated into usual care.
Example 1
We developed and tested a decision support interven-
tion based on the Ottawa Decision Support Frame-
work, which provides an approach to supporting 
individuals in making high-quality decisions that are 
informed and consistent with their values.62 In the 
context of prostate cancer testing, we would add that 
a high-quality decision is one that is consistent with 
men’s preferences.20 The Ottawa framework identi-
fies determinants of suboptimal healthcare decisions 
that may be modified by decision support interven-
tions, including: problems with perceptions of the 
decision (eg, inadequate knowledge, unclear values, 
decisional conflict), perceptions of others (eg, limited 
knowledge of others’ opinions and practices, inade-
quate support), and personal and external resources 
to make the decision (eg, ability to talk with a physi-
cian).63 The present intervention addressed these 
problematic determinants of prostate cancer testing 
decisions. [Introduction]
[…]
We hypothesised that relative to men randomised 
to an attention control condition, men randomised 
to a prostate cancer decision support intervention 
condition would have: greater gains in knowledge 
about prostate cancer and prostate cancer testing, 
lower decision conflict, greater likelihood of talking 
with their doctor about prostate cancer testing and 
greater likelihood of acting on their intentions to test. 
[Introduction]
Knowledge was assessed with a 14-item index … . 
Decision conflict related to prostate cancer testing was 
measured using a modified version of the validated 
Decisional Conflict Scale (DCS).64 … At post-test, they 
reported whether they had visited their primary care 
physician and discussed testing since the pre-test inter-
view … . At post-test, men were asked whether they had 
"decided to get tested in the future for prostate cancer" 
(no/yes). This measure of testing intention indicates 
men’s preference for testing or not testing.55 [Methods]
Example 2
According to Fuzzy Trace Theory,65 it is possible that 
participants made an initial decision at post-test based 
on their knowledge and attitudes at that time, and 
then forgot details by follow-up but remembered their 
general decision. These participants would, therefore, 
make a decision at follow-up based on their initial 
(post-test) knowledge and feelings. Three different 
‘informed decision’ scores were calculated to account 
for the various ways participants may have arrived at 
an informed decision. Post-test knowledge, attitudes 
and intentions were used for the ‘post-test informed 
decision’ score. Follow-up knowledge, attitudes and 
behaviour were used for the ‘follow-up informed deci-
sion’ score. Finally, post-test knowledge and follow-up 
attitudes and behaviour were used for the ‘latent 
knowledge informed decision’ score.66
Explanation
These examples show that the authors used measures 
to evaluate the PDA in the context of the theories or 
frameworks that guided their PDA development and 
evaluation. Example 1 describes development based 
on the Ottawa Decision Support Framework,46 identi-
fies targeted outcomes based on that and lists outcome 
measures appropriate to the framework. Example 2 
quotes Fuzzy Trace Theory65 and explains the timing 
of measurement of informed decisions using measures 
of knowledge, attitudes and intentions or behaviour, 
at different time points postintervention. The specific 
frameworks or theories are named and referenced. 
Readers can trace the constructs and concepts assessed 
by each measure back to the conceptual framework.
Item 17
For all study measures used to assess the impact of the 
patient decision aid on patients, health professionals, 
organisation and health system:
 ► Identify the measures
 ► Indicate the timing of administration in relation to expo-
sure to the PDA and healthcare interventions.
Item 17 links to item 18, reporting the name and 
properties of the specific instruments used. A descrip-
tion and rationale explaining the study measures 
enables readers to evaluate the quality of measurement 
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at multiple levels. First, linking the measure to the 
theory or conceptual framework of the study allows 
readers to consider the appropriateness of the measure 
for addressing the aims of the study (eg, process vs 
outcome; proximal vs distal outcomes) in relation 
to the theory/framework (see item 16). Describing 
the administration of study measures allows readers 
to assess potential threats to internal design validity 
(eg, when ‘decision-making satisfaction’ is measured 
immediately after the PDA or measured after the PDA 
and physician consultation). This description also 
allows readers to weigh the scope and potential impact 
of the results and interpretation for patients, practi-
tioners and/or public health. These descriptions also 
facilitate methods reviews to further evaluate the use, 
effectiveness and opportunities for improvement of 
the measures.
Example 1
After the office visit, subjects in the intervention 
groups completed a post-visit assessment, including 
a rating of the videotape presentation. Telephone 
follow-up assessments were conducted at 2 weeks after 
the baseline assessment and intervention. The same 
knowledge measure was administered at follow-up. … 
At the 2-week follow-up assessment, subjects in the 
intervention groups were asked the degree to which 
their preferences for PSA testing were influenced by 
the videotape and whether they would recommend it 
to other patients.67
Example 2
Research assistants … scheduled a study visit 1 hour 
before their next clinic visit. After viewing their 
randomly assigned video, participants completed 
postintervention questionnaires … . Postintervention 
questionnaires assessed participants’ knowledge, deci-
sion-making and screening behaviours. The low-lit-
eracy 10-item Decisional Conflict Scale and four 
subscale (Informed, Value Clarity, Support and Uncer-
tainty) scores were summed (yes=0, unsure=2 and 
no=4) and scaled to a maximum of 100 points, with 
lower scores indicating less conflict.22 The 12-item 
Patient Self-Advocacy Scale was scored (yes=1, 
unsure=2, no=3), summed and divided by 12 for an 
average score, with lower scores indicating greater 
self-advocacy.23 Chart review at three months after the 
study visit confirmed colorectal cancer screening test 
orders and completion.68
Example 3
We measured three types of outcomes in this study: 
effectiveness, acceptability, and cost-effectiveness. 
Effectiveness outcomes were divided into three cate-
gories. Our primary effectiveness outcome was change 
in 10-year predicted CHD [coronary heart disease] 
risk in participants without known CVD [cardiovas-
cular disease]. Secondary outcomes were measured 
in participants both without and with known CVD 
and included changes in blood pressure, cholesterol, 
aspirin use, medication adherence, dietary behav-
iours, and physical activity. Tertiary outcomes were 
measured in all participants and included weight, body 
mass index (BMI), general quality of life and outcomes 
related to possible harms (liver function tests (LFTs) 
and creatinine (Cr)). All outcomes were measured at 
both 4 months (primary timeframe) and 12 months 
in both study arms. The details of measurements are 
described below … .41
Explanation
Example 1 is clear about the timing of the measures 
with respect to the index clinic visit and viewing of the 
PDA, although it does not clearly identify the meas-
ure(s). Example 2 clearly identifies the measures used 
and states that they were administered after viewing 
the PDA but before the initial clinic visit. Example 3 
lists the range of measures used, categorised by type of 
outcome, and their timing, and indicates that further 
detail is included later (see item 18).
Item 18
For any instruments used:
 ► Name the instrument and the version (if applicable)
 ► Briefly describe the psychometric properties, or cite oth-
er documents.
Descriptions of the instruments used and their 
psychometric performance are essential for enabling 
readers to assess the appropriateness of the instrument 
for capturing the intended constructs, the use of the 
instrument relative to its original design and the inter-
pretation of results. However, a critical appraisal7 of 
the PDAs included in the updated Cochrane review3 4 of 
PDAs noted that very few studies reported the psycho-
metric properties of the measures. Even for a ‘valid 
and reliable’ measure, care should be taken to report 
if it has been validated in the specific study population 
and context, and/or whether any modifications have 
been made to the instrument or scoring. A full descrip-
tion of the instruments used is recommended,7 either 
in the text or as an appendix; however, citations may 
suffice for well-established measures, provided that no 
instrument modifications have been made.
Example 1
The study website presented the three postdecision aid 
scales (see table 1 [in original paper] for psychometric 
properties). … . The Osteoarthritis Decision Quality 
Index, Knowledge Subscale contains five multi-
ple-choice items assessing understanding of key facts 
about the treatment options.69 The interactive capa-
bilities of the web-based research platform allowed for 
adaption of the paper version to provide interactive 
corrective feedback (ie, if an incorrect answer was 
selected, the correct answer was presented). … The 
website then presented the 11-item Preparation for 
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Decision Making Scale and the 10-item low-literacy 
DCS.23
Example 2
We administered the standard 16-item version and 
a 10-item low-literacy version of the DCS64 at the 
high-literacy and low-literacy sites, respectively. The 
standard version includes five subscales: (1) uncer-
tainty or lack of assuredness about the decision, (2) 
feeling informed about the options and their benefits 
and risks, (3) feeling clear about one's personal values 
in making the decision, (4) feeling social support in 
making the decision and (5) feelings of having made 
an effective decision and planning to follow through. 
The subscales have excellent internal-consistency reli-
ability (alpha range: 0.78–0.92) and construct validity. 
The low-literacy version uses a question-and-answer 
format with three response options: ‘yes’, ‘no’ or 
‘unsure’. The version has good internal-consistency 
reliability (alpha, 0.86) and evidence of responsive-
ness to change after a decision aid is delivered. Scoring 
conventions followed the new DCS manual, wherein 
scores are expressed on a 0 (low decisional conflict) to 
100 (high decisional conflict) scale.70
Explanation
Example 1 illustrates a concise statement that provides 
the essential information plus reference to more detail 
in a table (provided in the original paper). The brief 
summary of the instruments may be sufficient for 
readers who are well-versed with these instruments, 
and the specific versions are referenced for researchers 
who wish to explore in more detail or replicate the 
study. The more detailed psychometric properties 
table allows readers to more deeply explore the theo-
retical constructs of the instruments and their quality. 
Alternatively, example 2 illustrates a concise paragraph 
providing the definition, theoretical constructs, poten-
tial responsiveness to PDAs, versions administered, 
psychometric performance, scoring and interpretation.
results
In addition to standard reporting of results:
Item 19
Describe the characteristics of the patient, family and 
carer population(s) (eg, health literacy, numeracy, 
prior experience with treatment options) that may 
affect patient decision aid outcomes.
Reporting the characteristics of patients, family 
and carers receiving PDAs in evaluation studies (eg, 
age, sex, health literacy, numeracy, race/ethnicity) is 
important for several reasons. Such characteristics may 
affect the effectiveness of the PDA. For example, lower 
health literacy is associated with lower knowledge 
scores, less desire for involvement in decision making 
and higher decisional conflict and regret scores.71 
Nonetheless, the 2014 IPDAS evidence review found 
that 90% of PDA trials did not report health literacy 
and readability, although studies that address health 
literacy show increased knowledge and informed 
choice.71 Similarly, race/ethnicity has been associated 
with differences in preferences for screening/treat-
ment, leading to development of PDAs tailored to 
different cultural contexts.68 72 73
Reporting participant characteristics also allows 
readers and reviewers to assess the generalisability of 
the study results. Reporting of participant characteris-
tics overall, by study arm and by important subgroups 
allows readers to assess the potential for selection bias 
or confounding, and can highlight populations within 
which the PDA may have differential effects (effect 
modification or moderation). Reporting is important 
because it also allows readers and reviewers to assess 
whether there may be important subgroups who may 
benefit more/less from the PDA. While most articles 
include sample characteristics in a table, it is important 
to report whether any analyses were done to test for 
differences among individuals who accepted/declined 
participation and to test for potential subgroup inter-
actions with the study outcomes. Explanations of any 
observed differences may be reported in the discussion 
or limitations (see item 24).
Additionally, reporting is needed for characteristics 
that are suspected to interact with decision making, 
to allow reviewers to identify studies for meta-anal-
yses. For example, as PDAs become increasingly avail-
able on the Internet, reporting participants’ level of 
digital comfort will facilitate assessments of web-based 
PDAs for individuals who are digitally naïve versus 
digitally savvy.12 Similarly, as patients become more 
familiar with shared decision making and/or suites of 
PDAs become available for progressive decisions (eg, 
chronic disease management), reporting patients' and 
caregivers’ familiarity with the decision context and 
decision self-efficacy will allow for analyses of PDAs 
that provide interactive levels of clinical information 
and/or deliberative support.23
Example 1
Table 2 [in original paper] presents bivariate relation-
ships among sociodemographic and health characteristics 
across the range of primary and secondary outcomes. 
Older men were more likely to demonstrate decisional 
consistency and had higher decisional conflict. White race 
was associated with decreased decisional self-efficacy.50
Example 2
Table 2 [in original paper] summarises the partic-
ipants’ [sociodemographic, cognitive and clinical] 
characteristics. Overall (n=126), study participants 
were primarily female, Caucasian, younger adults 
with college degrees and moderate knee pain. . … The 
study sample may have contributed to a type II error 
in terms of their high baseline familiarity [with their 
condition and treatment]. … Different results may be 
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observed with PDAs that focus on the first decision in 
a chronic condition, or on clinical situations that are 
acute, life threatening or involve surrogate decision 
making.23
Example 3
There were no differences between those who partic-
ipated and those who declined. … Income, educa-
tion and race were significantly related to outcome 
variables at the bivariate level and were included in 
multivariate analyses in addition to gender. … Health 
literacy was significantly related to knowledge of 
health insurance information. … A similar pattern was 
seen for numeracy skills.74
Explanation
While patient characteristics are typically presented in 
a table, the above examples illustrate ways to clarify 
in the text whether/how patient characteristics may 
be related to the study outcomes. Example 1 presents 
the patient characteristics in a table in the Results 
showing about 90% of participants were white, 
non-Hispanic. The extract above (from the paper’s 
Discussion) explains how the sample population may 
not address the needs of an important subgroup of 
the target population and touches on the generalis-
ability of the findings. Example 2 discusses how the 
characteristics of the sample (eg, chronic condition) 
may have contributed to the high observed knowl-
edge, preparation and self-efficacy scores. Example 3 
clearly reports data to assess selection bias and several 
participant characteristics that were associated with 
study outcomes.
Item 20
Describe any characteristics of the participating health 
professionals (eg, relevant training, usual care vs study 
professional, role in decision making) that may affect 
decision aid outcomes.
Reporting the characteristics of health professionals 
who are involved in evaluation studies (eg, training, 
seniority, coaching, meeting with patients, delivering 
PDAs) is important for several reasons. As part of 
the delivery of a complex intervention, their char-
acteristics may affect the effectiveness of the PDA. 
For example, whether they have been trained in the 
delivery of the PDA or in shared decision making 
will have potential impact on effectiveness. Whether 
the clinicians involved are research staff employed 
for the study itself, or the patient’s usual responsible 
clinician may also impact on the patient, for example, 
it may influence whether patients see this as part of 
their normal care, thus supporting actual decision 
making (‘patienthood’), or whether they see them-
selves more as trial participants (‘volunteerism’) rather 
than patients considering active treatment choice. A 
secondary analysis of the Cochrane review PDA data-
base suggested that patient knowledge is greater in 
‘patienthood’ trials.75
To allow reviewers to ascertain the influence of 
health professionals on the effectiveness of the PDA, 
important characteristics about the background and 
training of the key health professionals involved in 
delivery (eg, role in decision-making process, experi-
ence) should be documented. Furthermore, this will 
provide those wishing to use the PDA in their clinic 
with information about the staff and/or training 
needed to successfully implement the PDA in a new 
practice.
Example 1
Two of the 10 physicians in the control group (20%) 
and 5 of the 15 in the intervention group (33%) were 
female [PDA for depression]. The mean age of the 
participating general practitioners was 48.4 years with 
a SD of 8.0 years (control group 47.4±7.2 years, inter-
vention group 48.9±8.4 years). The average years 
professional experience was 13.0±7.0 years (control 
group 10.6±7.4 years, intervention group 14.3±6.7 
years). Gender, age and professional experience did not 
differ significantly between study groups (P>0.10).51
Example 2
A total of 19 physiotherapists were involved in the 
trial [PDA for low back pain]. Twelve physiotherapists 
were present at the start of the trial, and seven were 
randomised to the decision support arm. Of the seven 
physiotherapists in the intervention arm, four had 
more than 6 years of experience, whereas of the five 
who were randomised to the control arm only one of 
them had more than 6 years of experience (table 1 [in 
original paper]). The other seven physiotherapists who 
joined the department after randomisation were allo-
cated to the control arm and four of them had more 
than 6 years of experience.76
Explanation
Example 1 clearly reports the mean age, gender and 
years of experience of the physicians involved in the 
study, as well as showing that the characteristics of 
the physicians were associated with patient outcomes. 
Example 2 describes the physiotherapists who deliv-
ered the intervention and control arms, and includes 
information on experience that might be important in 
interpreting the study findings or using the PDA subse-
quently in practice.
Item 21
Report any results on the use of the patient decision 
aid:
 ► How much and which components were used
 ► Degree to which it was delivered and used as intended 
(also known as fidelity).
The impact of PDAs depends on the quality of the 
PDA and on whether, and how well, it was delivered 
and used. For a variety of reasons, PDAs, or parts of 
them, may not be delivered and/or used as they were 
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initially intended. This is also known as fidelity of the 
intervention and has significant implications for the 
success of the PDA. If fidelity is assessed, as per item 
14, the authors should report results of the extent to 
which the PDA was delivered and used as intended, to 
allow readers to critically appraise differences between 
how the PDA was intended to be used and how it was 
actually delivered and used, and the impact of any 
differences on the effectiveness of the intervention 
(positive or negative).
Regardless of fidelity, it is also valuable to have data 
on how the PDA was used, for example, whether all 
components were viewed and for how long. Such data 
are valuable to understand, for example, to what extent 
use may have impacted on measured effectiveness.
Such information can help (a) explain the study find-
ings, that is, determine the extent to which the study 
outcomes were related to the quality of PDA delivery 
and rates and ways of PDA uptake; (b) make infer-
ences about what processes may have mediated the 
relationship between the PDA intervention and study 
outcomes and (c) plan further studies or strategies to 
improve fidelity, uptake and adherence.12
Example 1
Allocation and reception of intervention
A total of 250 patients (n=124 intervention vs 
n=126 control) were included in the trial, of whom 
73 completed the follow-up measurement and were 
included in the final analysis (response rate 29.2%). 
Of these 73 patients, 40 were in the intervention and 
33 in the control condition. Of the 40 patients in the 
intervention condition who completed the follow-up 
measurement, 30 used the decision aid. A detailed 
overview of the flow of participants is presented in 
figure 4 [in original paper].58
Example 2
Contamination and fidelity
The appendix (online) describes the [fidelity] check-
list and the results of the contamination and fidelity 
evaluation. Of 12 maximum points, encounters in 
the decision aid arm had a fidelity score of 8 (3–12), 
whereas encounters in the usual care arm had a 
contamination score of 1 (0–8). Usual care encounters 
of clinicians who had used the decision aid previously 
had a contamination score of 1 (0–6).54
Example 3
Although the patient narratives were available to all 
participants in the narrative conditions, not all partic-
ipants chose to view the narratives while reviewing 
the [breast cancer] decision aid. Table 3 [see Table 1 
included] describes the content of each narrative, indi-
cates the proportion of times that narrative was viewed 
in both the text and video narrative conditions and 
displays the mean time spent on the webpage with that 
narrative. Note each narrative was located on a sepa-
rate webpage that would open when users clicked on 
Table 1 Time spent viewing the patient and physician interviews [reprinted with permission from Shaffer et al77]
Title of content
Includes 
patients
Includes 
physicians
Text narratives 
(n=10) Video narratives (n=17)
% View 
(n)
Mean 
time on 
page, 
seconds
% View 
(n)
Mean time on 
page, seconds
Description of diagnosis ✔ ✔ 60 (6) 67.28 47 (8) 117.19
A woman’s preference is important ✔ 50 (5) 18.79 35 (6) 30.92
Take your time making a decision ✔ ✔ 60 (6) 27.96 35 (6) 87.09
Types of breast cancer ✔ 30 (3) 20.93 59 (10) 44.70
Pathology report ✔ 40 (4) 16.39 59 (10) 36.37
Why two patients chose mastectomy ✔ 50 (5) 23.74 65 (11) 48.98
Appearance after mastectomy ✔ 80 (8) 21.24 53 (9) 50.57
Breast reconstruction ✔ 70 (7) 7.75 53 (9) 19.14
Why patient A chose lumpectomy ✔ 50 (5) 5.00 53 (9) 15.11
Why patient B chose lumpectomy ✔ 50 (5) 11.38 59 (10) 27.86
Radiation after lumpectomy ✔ ✔ 50 (5) 23.50 65 (11) 57.71
Side effects of radiation ✔ 40 (4) 15.71 47 (8) 30.15
Appearance after mastectomy ✔ 50 (5) 17.60 41 (7) 29.10
Sentinel node biopsy ✔ 30 (3) 34.32 47 (8) 51.77
Side effects of lymph node surgery ✔ 40 (4) 16.62 41 (7) 35.16
Being involved in treatment decisions ✔ 70 (7) 8.13 53 (9) 28.64
Making decisions ✔ 60 (6) 25.29 47 (8) 73.42
Life after breast cancer ✔ 50 (5) 15.71 53 (9) 47.56
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the content. This allowed us to track use of narrative 
information separately from information search in the 
rest of the decision aid. The narratives were accessed 
at a similar rate in both the text and video narrative 
conditions. However, participants in the video narra-
tive conditions spent more time with the narratives 
than participants in the text narrative conditions.77
Explanation
In example 1, the authors provide precise data on the 
numbers of participants who received the PDA and 
those who actually used it. From these data, it is clear 
that, although the PDA was delivered to 40 partici-
pants, not all of them actually used it. The authors 
in example 2 used a checklist to assess fidelity in the 
intervention as well as control arms and reported 
the results of this assessment. The data suggest that 
the PDA was used as intended, and that there was 
no contamination in the usual care arm. Example 3 
provides data on both the frequency and time spent by 
patients who accessed text or video narratives (similar 
rates of access but more time spent with video narra-
tives).
Item 22
Report relevant results of any analyses conducted to 
understand how and why the patient decision aid 
works (also known as process evaluation).
Reporting the results of a process evaluation allows 
the reader to understand what happened with the 
delivery of the PDA within the context of the partic-
ular evaluation study. This enables the reader to put the 
results in context and interpret them with reference to 
how the PDA was used. Process evaluation thus allows 
an understanding of how and why the PDA worked (or 
did not work), including the factors that might explain 
or affect the impact (see item 15).
Example 1
In the process evaluation, we collected data to answer 
five questions about potential problems related to 
implementation and context [of a web-based PDA for 
people with a psychotic disorder]. … 
The fourth question was: Could any problems 
be observed with fulfilment of the study protocol? 
Through researcher observation, several recurring 
themes were identified during clinical meetings in 
which the trial was discussed. Case managers some-
times were hesitant and felt troubled to invite inter-
vention patients to make use of the decision tool. 
First, they were doubtful whether patients were able 
to handle either the computer program or participa-
tion in a research trial. Second, they were not sure that 
patients would benefit from the decision aid because 
not all treatment options included in the decision aid 
were actually offered by their organisation (eg, music 
therapy was listed among the treatment options, but 
no music therapy was currently offered because of 
absence of a music therapist). In addition, various 
clinicians reported that they were unsure when to 
discuss outcomes of the decision aid with their patients 
because not all conducted a formal treatment evalua-
tion session with their patients following their ROM 
[routine outcome monitoring] assessment. Some only 
discussed ROM results within the clinical team and 
not directly with patients.
The fifth question was: Did patients experience any 
problems with the intervention that was not covered 
in the satisfaction questionnaire? Open interviews 
among patients who chose to use or not use the website 
provided some additional details on the process. First, 
all patients were initially informed about the decision 
aid by an information booklet and in a meeting with a 
research nurse, but most of them received additional 
explanation from their case manager. Some framed 
the decision aid predominantly within a research 
context ("by using the decision aid, you contribute to 
research"), whereas others described it as an attempt 
to improve services ("using the decision aid might help 
you reflect on the treatment you want"). This might 
have affected patients’ expectations of the interven-
tion. Moreover, interviews revealed discrepancies 
between the policy of the local disease management 
programme and patients’ experiences in clinical 
practice. Most of the interviewed patients could not 
remember their ROM results being discussed with 
them and some could not remember whether a treat-
ment plan was created.58
Example 2
Concerns about the participants’ use of the standard 
gamble exercise were first raised with researchers by 
a clinic doctor. He was worried that participants did 
not grasp the purpose of the exercise and reported 
difficulties working through the standard gamble with 
them. Initial qualitative analysis of the consultation 
videos and concomitant analysis of the interviews 
revealed that participants were confused about the use 
and purpose of the standard gamble. Further in-depth 
analysis of video and interview data … confirmed 
that participants experienced problems with both 
understanding and carrying out the standard gamble. 
[Results]
We examined the videos and post hoc interviews 
for confirming and disconfirming examples of these 
problems and determined that six of eight participants 
in this explicit arm experienced these problems, and 
were unable to carry out the standard gamble exercise. 
[Results]
On the basis of the analysis of the videos and inter-
views [a] decision was taken to discontinue the explicit 
arm of the trial on the basis of the qualitative anal-
ysis, which demonstrated that the standard gamble 
value-elicitation exercise was causing confusion and 
was unlikely to produce valid data on patient values. 
It was believed that it would be unethical to continue, 
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and also that the results would be distorted or impos-
sible to interpret.59 [Discussion]
Explanation
In the first example, this extracted section of the 
results clearly describes important contextual factors 
that might influence interpretation of the results or 
subsequent implementation efforts. With respect to 
the fulfilment of the protocol, the authors demon-
strate that having a PDA with options that are not 
available within the health system may impact on use 
of the PDA. The interviews with patients illuminate 
two challenges. First, the way that patients position 
themselves (within a research context or as an aid to 
their decision making) that might influence the use 
or outcome of the PDA (which has also been demon-
strated elsewhere and with some evidence from a suba-
nalysis of Cochrane that this might be important for 
interpretation and implementation).75 78 Second, there 
were findings suggesting that the service aims were not 
being achieved as a result of patients not recalling their 
results or a treatment plan.
In the second example, the extract is from a process 
evaluation undertaken and published alongside the 
trial, which surprisingly revealed that one version of 
the PDA (a computerised PDA using standard gamble 
as an explicit values clarification technique), which 
had been developed in codesign with end users, was 
problematic for patients in the trial. This was suffi-
ciently troublesome to lead to discontinuation of 
one arm of the trial on ethical grounds. The results 
are summarised in the above extract; the full paper 
includes quotes from interviews and direct observa-
tions from video recordings.
Item 23
Report any unanticipated positive or negative conse-
quences of the patient decision aid.
Reporting unexpected consequences is an ethical 
imperative for researchers. Such consequences could 
be adverse (such as increased decisional conflict 
or additional service costs/utilisation) or beneficial 
(such as increased gains for subgroups of the popula-
tion). Reporting of unanticipated positive and nega-
tive consequences supports systematic review and 
meta-analysis of the effectiveness of PDAs. It can also 
alert researchers, clinicians and policymakers to poten-
tial emerging areas of interest.
Example 1
Interaction Effects Between SDMI [shared decision- 
making intervention] and Cancer History
From the separate analyses for affected [past 
history of breast or ovarian cancer] and unaffected 
women [no past history]. … In the short term, … the 
SDMI [shared decision-making intervention] had no 
effect on affected or on unaffected women. In the 
long term, for unaffected women, beneficial effects 
were found on all outcome measures and most were 
significant. The effect sizes were larger for unaffected 
women compared with the whole group. … For 
affected women, insignificant detrimental effects were 
found on the above-mentioned outcomes for which an 
interaction effect was found.79 [Results]
Example 2
The study did not find a significant difference between 
using an implicit or explicit deliberative guidance 
approach, on average, for decisions about surgical 
versus non-surgical management of chronic knee 
osteoarthritis. However, results indicate that there 
are some subgroups of patients who exhibit different 
deliberative styles, in terms of information seeking and 
deliberative engagement. Higher levels of informa-
tion-seeking and active-engagement were associated 
with lower decisional conflict levels. Higher levels of 
active-engagement were associated with higher levels 
of decision self-efficacy. …
This information may be useful to clinicians who 
wish to increase the patient-centeredness of their deci-
sion support interventions. … Assessing the match 
between patients’ needs and decision aid design 
elements may play an important role in addressing 
the marked variations observed in the rates of surgery 
for chronic conditions, such as knee osteoarthritis. It's 
possible that observed geographic variations are genu-
inely warranted, if well-informed patients are receiving 
the care that they clearly value.80
Explanation
Example 1 is taken from a trial of a PDA that was 
developed for women who were BRCA1/2 mutation 
carriers, and therefore at increased risk of breast and 
ovarian cancer, who are faced with the choice between 
screening and prophylactic surgery for breasts and/or 
ovaries. The study sample included women who had 
not had cancer (unaffected) as well as those who had 
already experienced either breast or ovarian cancer 
(affected). The PDA (referred to as SDMI) showed 
an overall beneficial effect for unaffected women, 
whereas affected women tended to experience detri-
mental effects. This example clearly states that nega-
tive outcomes were encountered in the subgroup who 
had previous cancer, as shown by interaction anal-
ysis. The authors were surprised by this finding and 
addressed several potential explanations in the Discus-
sion section but concluded that "it remains unclear 
why the SDMI is not effective in affected women".79
Example 2 illustrates the reporting of an unexpected 
benefit of the subgroup analyses: decision-making 
outcomes were improved when the web-based PDA’s 
interactive features enabled them to ‘match’ their 
preferred information-seeking/deliberative styles (ie, 
high/low engagement). Reporting these unexpected 
findings allows future PDA designers and researchers, 
as well as clinicians, to consider the potential value 
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targeting and/or allowing patients to self-tailor the 
information and support they need.
discussion
As part of the standard discussion section (summary 
of key findings, interpretation, limitations and conclu-
sions):
Item 24
Discuss whether the patient decision aid worked as 
intended and interpret the results taking into account 
the specific context of the study including any process 
evaluation.
The discussion of the paper provides a summary of 
the findings with acknowledgement of the context and 
other factors that may have influenced the findings. 
For example, discussion should explain any findings 
on whether or how the PDA worked (or did not work) 
based on: use of the PDA or use as intended (fidelity; 
see items 14 and 21); analysis by patient or clinician 
characteristics (see items 19 and 20) and the context 
of the study, including any results from process evalu-
ation (see items 15 and 22).
Example 1
Measuring decision quality as a composite measure was 
possible in this study. A quality decision, the ultimate 
goal of PDAs, is ideally measured by using patient’s 
score on the knowledge test as an indicator of being 
informed, and measuring the concordance between 
the informed patient’s values for outcomes of options 
and the actual choice of surgery (or non-surgery). In 
this study, patients exposed to the PDA intervention 
obtained significantly higher decision quality (56%) 
compared with those who received usual education 
(25%).81
Example 2
Not all patients in the intervention group were actu-
ally offered the possibility to use the decision aid and, 
more importantly, ROM [routine outcome monitoring] 
and treatment evaluation meetings in which the treat-
ment plan was to be discussed in a process of shared 
decision making did not always take place. More-
over, interviews indicate that the Web-based interven-
tion might have been framed differently to different 
patients, which may have shaped their expectations 
and affected their evaluation. An interesting finding in 
the process evaluation was that patients who perceived 
their involvement in medical decision making as low 
were judged by clinicians to be less capable of partic-
ipating in decision making. This could imply that 
patients participate less because they are less capable. 
Nevertheless, we cannot rule out that patients partici-
pate less because clinicians consider them less capable 
and, therefore, provide less opportunities for patients 
to participate in decision making.58
Example 3
Our results show an effect size on decisional conflict 
that is comparable to other studies of decision aids, 
suggesting that the computerised decision aid does 
have a measurable and clinically important impact that 
is greater than the doctor-led paper-based guidelines.
Each clinic [intervention and control] was delivered 
by a single [different] doctor, raising the question as 
to whether the findings reflect the different interven-
tions, the different doctors delivering the interventions 
or some combination of the two. In some respects this 
is a false distinction; we were evaluating a package of 
decision support, and we attempted to minimise any 
doctor-specific effect by training the doctors in the 
intervention and the desired mode of delivery.57
Explanation
Examples 1 and 3 clearly indicate that the PDA worked 
as intended in terms of the expected findings. Example 
3 discusses several observations from the process eval-
uation that might impact on the interpretation of the 
findings, and would also be of value to others seeking 
to implement the PDA (or indeed seeking to imple-
ment other PDAs where similar context might be 
important). Example 3 also discusses the potential 
influence of the context on the process of delivering 
the PDA, and reflects on the importance, or otherwise, 
of this context.
Item 25
Discuss any implications of the results for patient deci-
sion aid development, research, implementation and 
theory, frameworks or models.
Identifying and discussing the implications of the 
study results helps readers understand the importance 
and potential impact of its findings. This item (specific 
to PDA studies) adds to the standard discussion items 
(ie, limitation, generalisability, interpretation) found in 
other reporting guidelines. Authors should place their 
findings in the context of what is already known about 
PDAs as well as, for example, current programme, 
policies, incentives, research and teaching initiatives 
that might support PDA implementation (see also 
item 24).
Example 1
Similar to previous investigators, we found that 
patients were more knowledgeable about the risks and 
benefits of various treatment alternatives for osteoar-
thritis of the hip or knee, were further along in their 
decision-making preconsultation, and had more confi-
dence in knowing what questions to ask their surgeon, 
on the basis of their responses to our pre-consulta-
tion survey. Surgeons also believed that patients who 
engaged in shared decision making asked more appro-
priate questions and made more efficient use of their 
time during their office visit. These findings could 
facilitate greater adoption of shared decision-making 
 o
n
 26 June 2018 by guest. Protected by copyright.
http://qualitysafety.bmj.com/
BM
J Qual Saf: first published as 10.1136/bmjqs-2017-006985 on 21 February 2018. Downloaded from 
408 Hoffman AS, et al. BMJ Qual Saf 2018;27:389–412. doi:10.1136/bmjqs-2017-006985
Research and reporting methodology
methods among orthopaedic surgeons, although many 
issues remain to be resolved.
Despite the well-documented benefits of shared 
decision making tools, they are not commonly used 
in orthopaedic surgery. There are currently many 
barriers to adoption, including the costs and logis-
tical challenges associated with the implementation 
of shared decision-making programs, lack of famil-
iarity and training in shared decision-making methods 
among surgeons, and a limited comparative effective-
ness research base available for developing decision 
aids. To facilitate widespread adoption of shared 
decision-making tools in orthopaedics, further work 
is needed to simplify and to reduce the cost of imple-
mentation, perhaps through the use of non-medi-
cally trained volunteers as coaches. Moreover, many 
healthcare stakeholders have portrayed shared deci-
sion making as reducing utilizationrates of elective 
surgical procedures such as total knee arthroplasty, 
which could make surgeons less eager to adopt these 
potentially value-enhancing tools, particularly in a 
fee-for-service payment system.82
Example 2
Implications for research and clinical practice. … 
For the use of PDAs, such as PANDAs [a PDA about 
glycaemic control], in routine clinical practice to 
become the accepted norm, the new GP [general prac-
titioner] clinical commissioning groups will need to be 
aware of the benefits of the use of such aids to ensure 
that decision aids become a professional standard in, 
for example, newly commissioned pathways for a 
long-term condition such as diabetes. Investment will 
also be necessary for the development and the contin-
uing evaluation of decision aid use, as well as for the 
training of all members of the multidisciplinary team 
in the importance and in the practical use of decision 
aids in primary care. Both the patient’s experience and 
patient/clinician satisfaction with the care received and 
provided is likely to be much improved if this profes-
sional standard is adopted by commissioning groups.83
Example 3
This study shows that the decision aid may be an 
effective way to support a screening policy that values 
informed choice and equity in access to informed 
choice, as opposed to policy focused on achieving high 
uptake. These results present an important dilemma 
for policy makers and healthcare providers on how to 
communicate to the public about screening.84
Example 4
When choosing visual aids to communicate statistical 
information, PtDA [patient decision aid] designers and 
providers should be aware of benefits and limitations 
of graphical representations—especially with more 
complex representations such as flowcharts. Incorpo-
rating comprehension checks into PtDAs would help 
identify misapprehension of graphically presented 
data and correct misunderstandings.85
Explanation
Example 1 describes the potential value of the find-
ings for implementation of SDM with orthopaedic 
surgeons, and then discusses wider issues in terms of 
potential barriers to use of PDAs and SDM in ortho-
paedic practice. The authors make suggestions for facil-
itating widespread adoption. These refer to the need to 
simplify and reduce the cost of implementation and the 
posited influence of fee for service systems on surgical 
acceptability were a PDA to lead to reduced uptake 
of the surgical intervention. Example 2 (in a section 
headed ‘Implications for research and clinical practice’) 
highlights the importance of healthcare commissioners 
in the English NHS and their critical role to support 
uptake of PDAs, as well as acknowledging the need 
for investment. Examples 3 and 4 briefly discuss the 
implications of the results with example 3 highlighting 
the impact that results from their study could have on 
supporting new policies or challenging existing ones for 
screening that are based on encouraging uptake rather 
than informed patient choice. Example 4 illustrates 
how findings from the study could influence how PDA 
developers choose and incorporate visual elements in 
the development of their PDAs.
conflict of interest
Item 26
All study authors should disclose if they have an 
interest (professional, financial or intellectual) in any 
of the options included in the patient decision aid or a 
financial interest in the decision aid itself.
Most journals require authors to state that they do 
not have conflicts of interest as a part of standard 
reporting. However, this is usually focused on finan-
cial aspects, such as funding, and may not specifically 
address professional or intellectual conflicts that are 
unique to PDAs. For example, potential interest in 
patients selecting one specific treatment option over 
others is unique to PDAs. Reporting of this item allows 
investigators, clinicians and readers to assess potential 
introduction of bias in the design, conduct, interpreta-
tion and reporting of studies of PDAs.
Example 1
Declaration of Personal Interests: Dartmouth-Hitch-
cock Medical Center and Cedars-Sinai Medical Center 
have a patent pending for a ‘System and Method of 
Communicating Predicted Medical Outcomes’, filed 
3/34/10. Dr Corey Siegel, Dr Lori Siegel and Dr 
Marla Dubinsky are inventors. CS, ST, MS, and MD 
are consultants to Prometheus Labs. CS, ST, and MD 
are consultants for AbbVie, Janssen, Takeda and UCB. 
MS is a consultant for AbbVie and Janssen. DM is a 
consultant for Genentech, Janssen, Ferring, Merck, 
and UCB.
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Declaration of Funding Interests: Dr Siegel is 
supported by AHRQ grant 1R01HS021747-01. There 
was no commercial support related to this project.86
Example 2
Competing interests: GE, M-AD and AB, authors on 
this paper, lead the Option Grid Collaborative and 
unincorporated association of individuals engaged in 
the development and dissemination of Option Grid 
decision aids for clinical encounters under the auspices 
of the Dartmouth Institute for Health Policy and Clin-
ical Practice. All authors have completed the Unified 
Competing Interests form at http://www. icmje. org/ 
coi_ disclosure. pdf (available on request from the 
corresponding author).87
Example 3
The Knowledge and Evaluation Research (KER) Unit 
at Mayo Clinic houses the processes of design and 
evaluation of decision aids, decides on topics of inves-
tigation, pursues funding, designs and conducts evalu-
ation trials and reports their findings. Investigators at 
the KER Unit, including authors of this manuscript, 
do not receive funding from any for-profit pharma-
ceutical or device manufacturer, nor do they receive 
any royalties or other monetary benefits, directly or 
indirectly, from the use of the decision aids. The KER 
Unit makes effective decision aids available online free 
of charge at http:// shareddecisions. mayoclinic. org.88
Explanation
Example 1 provides a potential example of how 
one might address potential conflicts of interest that 
include the more traditional financial ones (eg, grant 
funding, industry consultation, salary), and go beyond 
that to intellectual issues (eg, patents of intellectual 
property). Example 2 addresses intellectual invest-
ment in a PDA among those who have developed it 
as a potential source of conflict of interest. Example 3 
in addition addresses the issue of potential gains to be 
made from the PDA itself.
summAry And conclusions
This E&E document provides descriptive rationale and 
illustrative examples of how to address each element 
included in the SUNDAE Checklist.90 This additional 
information can support authors in addressing the 
guidelines when preparing reports of evaluations of 
PDAs for publication. The SUNDAE Checklist and 
accompanying E&E may also be of value to journal 
editors who may wish to reference them in author 
guidelines and within guidance for reviewers.
This E&E, along with the SUNDAE Checklist, 
and appendix (ie, the table of types of evidence 
supporting the Checklist items) are also available on 
the IPDAS website (http:// ipdas. ohri. ca/ resources. 
html) to promote public access. The Checklist should 
be used alongside other relevant reporting guidelines, 
such as CONSORT-PRO89 (CONsolidated Standards 
of Reporting Trials Patient-Reported Outcomes) 
for RCTs reporting patient-reported outcomes or 
TIDieR90 (Template for Intervention Description and 
Replication) for describing interventions.
The IPDAS reporting guidelines workgroup will 
continue to monitor and improve the materials. To 
that end, the corresponding authors welcome feed-
back and comments, particularly from those who use 
the Checklist and E&E, so that we can ensure they are 
updated and improved over time.
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